RALEIGH, N.C., Dec. 4, 2018 /PRNewswire/ -- Arrevus Inc. (www.arrevus.com), a biotechnology company developing solutions to treat infections in immune-compromised patients, received a $300,000 STTR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to develop a compound library and screening platform of DnaK inhibitors, a new class of anti-infectives to treat antibiotic resistant infections.
"We appreciate the NIH's support to develop more specific treatments for antibiotic resistant infections. Working with our colleagues at the University of Montana's Medical Biofilms Laboratory, we have a great opportunity to identify superior therapies for diseases with few therapeutic options," said Carl N. Kraus, M.D., President and CEO of Arrevus.
- Highly conserved bacterial heat shock protein
- Critical for
- Protein folding
- Biofilm formation
- Immune modulation
- Stress responsiveness (including response to antibiotic exposure)
A library of DnaK inhibitors will enable Arrevus to optimize individual DnaK sequences for each specific bacterial disease. The NIH's support is critical in developing this valuable screening platform.
About the IDEA Platform
Arrevus is exploiting a unique approach to the management of bacterial drug resistance utilizing the Insect Derived Anti-Infectives (IDEA) platform. The IDEA platform leverages millions of years of natural selection to identify and isolate fast acting, effective compounds that impact both the immune response as well as bacteria. These peptides, derived from insect templates, are screened in novel ways to predict the most active leads to treat human disease.
Arrevus is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs). Arrevus is headquartered in Raleigh, NC. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected].